A Case of Effusive Myocarditis as a Result of the Immune Checkpoint Inhibitor, Nivolumab

Gershon Koshy; Andrew Hale; Dev Jaiswal; Daniel Wildes; Mousumi Som

A Case of Effusive Myocarditis as a Result of the Immune Checkpoint Inhibitor, Nivolumab

Gershon Koshy
, Andrew Hale
, Dev Jaiswal
, Daniel Wildes
, Mousumi Som

Internal Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Immune checkpoint inhibitors (ICIs) are approved for the treatment of many different cancers.
Since their arrival, these agents have offered improved disease outcomes including a longer
duration of overall survival. [1] There does remain however several uncommon yet severe
adverse side effects from this drug class including cardiotoxicity

Original language	American English
Journal	Oklahoma State Medical Proceedings
Volume	4
Issue number	3
State	Published - 7 Dec 2020

Access to Document

https://okstatemedicalproceedings.com/index.php/OSMP/article/view/124

Cite this

@article{d1563385fffc4cc3803b58bbfb4f537f,

title = "A Case of Effusive Myocarditis as a Result of the Immune Checkpoint Inhibitor, Nivolumab",

abstract = "Immune checkpoint inhibitors (ICIs) are approved for the treatment of many different cancers. Since their arrival, these agents have offered improved disease outcomes including a longer duration of overall survival. [1] There does remain however several uncommon yet severe adverse side effects from this drug class including cardiotoxicity",

author = "Gershon Koshy and Andrew Hale and Dev Jaiswal and Daniel Wildes and Mousumi Som",

year = "2020",

month = dec,

day = "7",

language = "American English",

volume = "4",

journal = "Oklahoma State Medical Proceedings",

issn = "2475-8914",

number = "3",

}

TY - JOUR

T1 - A Case of Effusive Myocarditis as a Result of the Immune Checkpoint Inhibitor, Nivolumab

AU - Koshy, Gershon

AU - Hale, Andrew

AU - Jaiswal, Dev

AU - Wildes, Daniel

AU - Som, Mousumi

PY - 2020/12/7

Y1 - 2020/12/7

N2 - Immune checkpoint inhibitors (ICIs) are approved for the treatment of many different cancers. Since their arrival, these agents have offered improved disease outcomes including a longer duration of overall survival. [1] There does remain however several uncommon yet severe adverse side effects from this drug class including cardiotoxicity

AB - Immune checkpoint inhibitors (ICIs) are approved for the treatment of many different cancers. Since their arrival, these agents have offered improved disease outcomes including a longer duration of overall survival. [1] There does remain however several uncommon yet severe adverse side effects from this drug class including cardiotoxicity

M3 - Article

SN - 2475-8914

VL - 4

JO - Oklahoma State Medical Proceedings

JF - Oklahoma State Medical Proceedings

IS - 3

ER -

A Case of Effusive Myocarditis as a Result of the Immune Checkpoint Inhibitor, Nivolumab

Abstract

Access to Document

Fingerprint

Cite this